Larry J. Jolivette, Ph.D., joined SK Life Science Labs in 2021 and is the Head of the Drug Metabolism & Pharmacokinetics (DMPK) and Safety Assessment functions. With a comprehensive understanding of the drug discovery and development process, Larry plays a critical role in guiding and executing our organization’s preclinical strategy.

Before joining SK Life Science Labs, Larry obtained more than 20 years of experience at GlaxoSmithKline developing scientists, contributing to corporate initiatives, leading discovery and early development projects across multiple therapeutic areas that included oncology, cardiovascular, and neurology, and providing critical insights on the developability of potentially transformative new medicines.

Throughout his career, Larry has focused on bringing better medicines to patients faster by improving the translational understanding of preclinical pharmacokinetic, metabolism, and efficacy models to clinical dose prediction. Proudly, he has been a central contributor to cross-functional teams that have advanced more than ten assets from the discovery setting to clinical investigation. Larry is driven by a strong commitment to scientific integrity, constant improvement, and delivery of life-saving medicines to patients.

Larry earned doctoral and master’s degrees in pharmacology from the University of Rochester and a bachelor’s degree in chemistry from Southern University and A&M College.